Sign in
CompletedPhase 3

Long-term Safety of TPN171H Tablet in Erectile Dysfunction.

Key facts

Who runs it
Vigonvita Life Sciences
Where
China34 sites in 1 countryChoose a country to see its sites
Trial code
Status
Completed
Phase
Phase 3
People taking part
472 people enrolled
Started
12 Apr 2024
Ended
5 Jun 2025
Type of study
Interventional
Treatments tested
  • TPN171H
Record updated
25 July 2025

Who can take part

Age
18 years to 75 years
Sex
Men only
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 30 criteriaShow less

Who can take part

  • 18 years to 75 years (inclusive)
  • Males with ED at least 3 months
  • IIEF-5 ≤ 21 at visit 1
  • Patients in a stable, heterosexual relationship during the study
  • At the end of the untreated baseline period, the following conditions are met:(1)The subject must make at least four attempts at sexual intercourse during the untreated baseline period. (2)At least 50% of attempts during this period must be unsuccessful,(unsuccess means at least one of the first three questions should be answered "No" in SEP).(3)5≤IIEF-EF≤25
  • Patients who are willing to have 4 or more attempts of sexual intercourse per month, demonstrated compliance with the study protocol, including drug administration, diary completion, and scheduled study visits, during the qualifying trial
  • Patients who are willing to take proper contraceptive during the study and within 3 months after the last dose
  • Patients who have voluntarily decided to participate in this study, and signed the informed consent form

Who cannot take part

  • Patients with ED, which is caused by spinal injury or have had a radical prostatectomy or other surgery
  • Patients who have a penile implant
  • Patients who do not respond to marketed PDE5 inhibitors or have adverse reactions that lead to drug discontinuation
  • CYP3A4 potent inhibitors, moderate inhibitors, and potent inducers need to be used during the trial or discontinued for less than 31 days before enrollment
  • Subjects who are taking nitrate or NO donor drugs, guanylate cyclase agonists and cannot be discontinued during the trial
  • Patients who have used other drugs in clinical trials within the last 1 month
  • Patients who have a history of hypersensitivity to other PDE5 inhibitors or TPN171H
  • Patients with ED, which is caused by any other primary sexual disorder
  • Patients with the following cardiovascular disease: Myocardial infarction or stroke within the last 6 months; Unstable angina or angina occurring during sexual intercourse; New York Heart Association Class 2 or greater heart failure in the last 6 months
  • Uncontrolled hypotension (<90/60mmHg) or uncontrolled hypertension (≥180/110mmHg)
  • Patients with active gastrointestinal ulcers and bleeding disorders
  • Patients who have a history of NAION, or with a known genetically degenerative retinopathy, including retinitis pigmentosa
  • Patients who have a history of sudden decrease or loss of hearing
  • Patients with a history of severe central nervous system injury or peripheral muscular neurological disease in the past 6 months
  • Patient with a history of malignancy
  • Patients whose partner is breastfeeding/pregnant/trying to become pregnant, has a gynecological disease or is restricted in their activities during treatment
  • Patients with hepatic or renal dysfunction as per the following: AST, ALT>3*ULN, serum creatinine exceeds 50% of the upper limit of normal value
  • Patients with anatomical malformations of the penis
  • Patients with primary hypoactive sexual desire
  • Patients with diabetic complications (diabetic nephropathy, peripheral neuropathy)
  • Patients with significant neurological abnormalities who are unable or unwilling to cooperate
  • For other reasons besides the aforementioned cases, patient whose participation is deemed inappropriate

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

This is a multicenter, open study to evaluate the long-term safety and efficacy of TPN171H in men with erectile dysfunction.

The group in the trial

  • TPN171H groupTreatment being tested

    10 mg/ time, as needed, it is recommended to take warm water within 0.5 to 4 hours before sexual activity.

    Treatment: TPN171H

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Multicenter, Open Study to Evaluate the Long-term Safety and Efficacy of TPN171H in Patients With Erectile Dysfunction
Record updated
25 July 2025